Expert Emphasizes Importance of Acalabrutinib Approval in MCL

December 14, 2017 – The treatment of patients with mantle cell lymphoma (MCL) has undergone immense progress in the past year, says Michael Wang, MD. One of the biggest developments was the recent FDA approval of acalabrutinib for patients with relapsed disease. The single-arm phase II ACE-LY-004 study of acalabrutinib was the basis for the approval of the oral BTK inhibitor, as it demonstrated compelling efficacy and a tolerable safety profile. At the time … (leggi tutto)